《国家基本药物目录》(2012年版和2018年版)与《世界卫生组织基本药物标准清单》(2023版)中眼科用药的比较和分析  

Ophthalmic medications in List of National Essential Medicines(Version 2012 and 2018)and WHO Model List of Essential Medicines(Version 2023)

作　　者：刘博 宋钦 王雪[2] 张亚同[3] LIU Bo;SONG Qin;WANG Xue;ZHANG Ya-tong(Department of Pharmacy,Beijing Xiaotangshan Hospital,Beijing 102211;Medical Information Research Lab/Medical Library,Xuanwu Hospital,Capital Medical University,Beijing 100053;Department of Pharmaceutical Science,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing Key Laboratory of Drug Clinical Risks and Personalized Medication Evaluation,Beijing 100730)

机构地区：[1]北京小汤山医院药剂科,北京102211 [2]首都医科大学宣武医院医学信息研究室/图书馆,北京100053 [3]北京医院药学部,国家老年医学中心,中国医学科学院老年医学研究所,药物临床风险与个体化应用评价北京市重点实验室,北京100730

出　　处：《中南药学》2024年第7期1934-1938,共5页Central South Pharmacy

基　　金：国家重点研发计划(No.2020YFC2009000,No.2020YFC2009001);北京小汤山医院扶持项目(No.汤2023-12)。

摘　　要：目的为我国《国家基本药物目录》中的眼科用药提供改进建议。方法采用描述性分析方法,将《国家基本药物目录》(2012年版和2018年版)与《世界卫生组织基本药物标准清单》(2023版)中眼科用药部分进行对比,重点比较药品种类、剂型、规格和备注等方面的差异。结果与2012年版相比,2018年版的《国家基本药物目录》在西药和中药方面都有药物的增减和调整。《国家基本药物目录》(2018年版)与《世界卫生组织基本药物标准清单》(2023版)在药品分类、剂型和规格等方面存在差异。《世界卫生组织基本药物标准清单》(2023版)提供了详细的药物功能介绍和补充说明,以及可替代方案(药物)。结论《国家基本药物目录》(2018年版)根据我国眼科疾病的特点和需求进行了调整,但仍有改进的空间。借鉴《世界卫生组织基本药物标准清单》(2023版)的分类方法、制定替代药物清单,完善备注和适应证,可以更好地为不同级别医疗机构提供指导,提高眼科用药的安全性和适用性。Objective To provide recommendations for the improvement of the National Essential Medicines List(NEML)for ophthalmic drugs.Methods Descriptive analysis was used to compare the National Essential Medicines List(Version 2012 and 2018,NEML-2012 and NEML-2018)with the World Health Organization Model List of Essential Medicines(Version 2023,WHO-EML-2023),focusing on the differences in drug types,dosage forms,specifications and notations of ophthalmic drugs.Results Compared with NEML-2012,NEML-2018 witnessed additions,removals,and adjustments in both western medicine and traditional Chinese medicine.Furthermore,disparities in drug classification,formulations,and specifications were observed between NEML-2018 and WHOEML-2023,which provided detailed descriptions of the functions of the medicines and supplementary descriptions,as well as alternative solution.Conclusion NEML-2018 has been revised to cater to the characteristics and requirements of ophthalmic diseases in China.However,there is still room for improvement.Adopting the classification of WHO-EML-2023,developing a list of alternative medicines,and improving remarks and indications provides guidance to different levels of healthcare institutions and helps improve the safety and applicability of ophthalmic medicines.

关 键 词：国家基本药物目录 世界卫生组织基本药物标准清单 眼科用药 药物分类 比较分析 

分 类 号：R95[医药卫生—药学]